Skip to main content

Advertisement

SpringerLink
Log in

TP53 codon 72 polymorphism and type 2 diabetes: a case–control study in South Indian population

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

TP53 functions primarily as a tumor suppressor, controlling a myriad of signalling pathways that prevent a cell from undergoing malignant transformation. This tumor suppressive function requires an activation and stabilization of TP53 in response to cell stressors. However, besides its cancer-preventive functions, TP53 is also known to be involved in diverse cellular processes including metabolism, reproduction, stem cell renewal and development. Indeed, several lines of evidence strongly suggest that TP53 plays crucial role in diabetes. A number of studies have evaluated the association of genetic alterations (single nucleotide variations) in TP53 gene with the development of diabetes. However, the results have not been consistent. The aim of this study was to evaluate whether the C/G polymorphism at codon 72 (Pro72/Arg72), located in exon 4 of TP53, is associated with type 2 diabetes in South Indian population. A total of 74 type 2 diabetic patients and 54 non-diabetic subjects were screened. None of the three genotypes, namely C/C (Pro/Pro), C/G (Pro/Arg), and G/G (Arg/Arg) was found to be significantly associated with type 2 diabetes in our study group. The findings of this study indicate that TP53 codon 72 polymorphism is not associated with increased risk of type 2 diabetes in South Indian population. Further studies with a large cohort size would be necessary to corroborate the observations of this study. Nevertheless, this study represents the first genetic analysis of TP53 variants in South Indian type 2 diabetic patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

SNP:

Single nucleotide polymorphism

RFLP:

Restriction fragment length polymorphism

BMI:

Body mass index

DM:

Diabetes mellitus

References

  1. Chakraborty A, Uechi T, Kenmochi N (2011) Guarding the ‘translation apparatus’: defective ribosome biogenesis and the p53 signaling pathway. WIREs RNA 2(4):507–522

    Article  CAS  Google Scholar 

  2. Kung CP, Murphy ME (2016) The role of the p53 tumor suppressor in metabolism and diabetes. J Endocrinol 231(2):R61

    Article  CAS  Google Scholar 

  3. Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54(6):1615–1625

    Article  CAS  Google Scholar 

  4. Labuschagne CF, Zani F, Vousden KH (2018) Control of metabolism by p53 cancer and beyond. Biochim Biophys Acta Rev Cancer 1870(1):32–42

    Article  CAS  Google Scholar 

  5. Lacroix M, Riscal R, Arena G, Linares LK, Le Cam L (2020) Metabolic functions of the tumor suppressor p53: implications in normal physiology, metabolic disorders, and cancer. Mol Met 33:2–22

    Article  CAS  Google Scholar 

  6. Wang X, Zhao X, Gao X, Mei Y, Wu M (2013) A new role of p53 in regulating lipid metabolism. J Mol Cell Biol 5(2):147–150

    Article  Google Scholar 

  7. Secchiero P, Toffoli B, Melloni E, Agnoletto C, Monasta L, Zauli G (2013) The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40. Acta diabetol 50(6):899–906

    Article  CAS  Google Scholar 

  8. Armata HL, Golebiowski D, Jung DY, Ko HJ, Kim JK, Sluss HK (2010) Requirement of the ATM/p53 tumor suppressor pathway for glucose homeostasis. Mol Cell Biol 30(24):5787–5794

    Article  CAS  Google Scholar 

  9. Franck D, Tracy L, Armata HL, Delaney CL, Jung DY, Ko HJ, Ong H, Kim JK, Scrable H, Sluss HK (2013) Glucose tolerance in mice is linked to the dose of the p53 transactivation domain. Endocr Res 38(3):139–150

    Article  CAS  Google Scholar 

  10. Lin HY, Huang CH, Wu WJ, Chang LC, Lung FW (2008) TP53 codon 72 gene polymorphism paradox in associated with various carcinoma incidences, invasiveness and chemotherapy responses. Int J Biol Sci 4(4):248

    CAS  Google Scholar 

  11. Bonfigli AR, Sirolla C, Testa R, Cucchi M, Spazzafumo L, Salvioli S, Ceriello A, Olivieri F, Festa R, Procopio AD, Brandoni G (2013) The p53 codon 72 (Arg72Pro) polymorphism is associated with the degree of insulin resistance in type 2 diabetic subjects: a cross-sectional study. Acta diabetol 50(3):429–436

    Article  CAS  Google Scholar 

  12. Bitti MM, Saccucci P, Bottini E, Gloria-Bottini F (2010) p53 codon 72 polymorphism and type 1 diabetes mellitus. J Pediatr Endocrinol Metab 23(3):291–292

    Google Scholar 

  13. Gloria-Bottini F, Banci M, Saccucci P, Magrini A, Bottini E (2011) Is there a role of p53 codon 72 polymorphism in the susceptibility to type 2 diabetes in overweight subjects? A study in patients with cardiovascular diseases. Diabetes Res Clin Pract 91(3):64–67

    Article  Google Scholar 

  14. Neri A, Gloria-Bottini F, Banci M, Magrini A, Bottini E (2017) Cigarette smoking increases the effect of *Arg/*Arg genotype of P53 codon 72 on the susceptibility to type 2 diabetes in overweight subjects. J Tob Stimul Dis 1(1):013–015

    Article  Google Scholar 

  15. Gaulton KJ, Willer CJ, Li Y, Scott LJ, Conneely KN, Jackson AU, Duren WL, Chines PS, Narisu N, Bonnycastle LL, Luo J (2008) Comprehensive association study of type 2 diabetes and related quantitative traits with 222 candidate genes. Diabetes 57(11):3136–3144

    Article  CAS  Google Scholar 

  16. Leroy B, Anderson M, Soussi T (2014) TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat 35(6):672–688

    Article  CAS  Google Scholar 

  17. Dumont P, Leu JJ, Della Pietra AC, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33(3):357–365

    Article  CAS  Google Scholar 

  18. Kung CP, Khaku S, Jennis M, Zhou Y, Murphy ME (2015) Identification of TRIML2, a novel p53 target, that enhances p53 SUMOylation and regulates the transactivation of proapoptotic genes. Mol Cancer Res 13(2):250–262

    Article  CAS  Google Scholar 

  19. Spitsina EV, NIu I, Chudakova DA, Nikitin AG, Svetlova GN, Soluianova TN, Strokov IA, Nosikov VV (2007) Association of polymorphous markers Pro72Arg and C (−594) CC OF TP53 gene with diabetic polyneuropathy in patients with type 1 diabetes mellitus living in Moscow. Mol Biol 41(6):989–993

    Article  CAS  Google Scholar 

  20. Bitti ML, Saccucci P, Capasso F, Piccinini S, Angelini F, Rapini N, Porcari M, Arcano S, Petrelli A, Del Duca E, Bottini E (2011) Genotypes of p53 codon 72 correlate with age at onset of type 1 diabetes in a sex-specific manner. J Pediatr Endocrinol Metab 24(7–8):437–439

    CAS  PubMed  Google Scholar 

  21. Burgdorf KS, Grarup N, Justesen JM, Harder MN, Witte DR, Jørgensen T, Sandbæk A, Lauritzen T, Madsbad S, Hansen T, Pedersen O (2011) Studies of the association of Arg72Pro of tumor suppressor protein p53 with type 2 diabetes in a combined analysis of 55,521 Europeans. PLoS One 6(1):e15813

    Article  CAS  Google Scholar 

  22. Sliwinska A, Kasznicki J, Kosmalski M, Mikołajczyk M, Rogalska A, Przybylowska K, Majsterek I, Drzewoski J (2017) Tumour protein p53 is linked with type 2 diabetes mellitus. Indian J Med Res 146(2):237–243

    Article  Google Scholar 

  23. Słomiński B, Skrzypkowsk M, Ryba- Stanisławowska M, Myśliwiec M, Trzonkowski P (2021) Associations of TP53 codon 72 polymorphism with complications and comorbidities in patients with type 1diabetes. J Mol Med 99:675–683

    Article  Google Scholar 

Download references

Acknowledgements

The authors are grateful to the patients and the healthy controls who have agreed to take part in this study. The authors thank Nitte (Deemed to be University) for providing resource and infrastructural support. The authors also acknowledge the help of Dr. Neevan D’Souza from KSHEMA in the statistical analysis of the data.

Author information

Author notes

  1. Harshitha K. Punja and Dechamma Pandyanda Nanjappa have contributed equally to this work.

Authors and Affiliations

  1. Department of General Medicine, KS Hegde Medical Academy, Nitte (Deemed to be University), Mangaluru, 575018, India

    Harshitha K. Punja & Sudhindra M. Rao

  2. Division of Molecular Genetics and Cancer, Nitte University Centre for Science Education and Research (NUCSER), Nitte (Deemed to be University), Kotekar-Beeri Road, Deralakatte, Mangaluru, 575018, India

    Dechamma Pandyanda Nanjappa, Nishith Babu, Krithika Kalladka ,  B. Shanti Priya Dias, Gunimala Chakraborty & Anirban Chakraborty

Authors
  1. Harshitha K. Punja
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dechamma Pandyanda Nanjappa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nishith Babu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Krithika Kalladka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Shanti Priya Dias
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gunimala Chakraborty
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sudhindra M. Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anirban Chakraborty
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HKP collected the samples and curated the clinical data. DPN performed the molecular studies and prepared the original draft. BSPD, NB and KK partly performed the experiments and analysed the data. GC participated in discussion and edited the first draft of the manuscript. SMR and HKP conceptualised the study and helped in clinical data compilation. AC supervised the work, analysed the data and edited the draft manuscript.

Corresponding author

Correspondence to Anirban Chakraborty.

Ethics declarations

Conflict of interest

The authors declare they have no conflict of interest.

Informed consent

Informed consent from the participants were obtained and the study was approved by Ethics Committee of Nitte (Deemed to be University, RefNU/CEC/2018/0).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

11033_2021_6505_MOESM1_ESM.tif

Supplementary file1 Fig. 1 An image showing agarose gel electrophoresis of PCR products of TP53 codon 72. M: 100bp DNA ladder, Lane 1-10: Amplified gene fragment of TP53 codon 72 (TIF 4256 kb)

11033_2021_6505_MOESM2_ESM.tif

Supplementary file2 Fig. 2 A representative image of RFLP analysis at codon 72 of TP53.The RFLP pattern obtained from each sample was compared with the control RFLP pattern to examine the genotype. M-100 base pair ladder; U-undigested PCR product; D-digested PCR product. Sample no. 1 and 5 showed-G/G (wildtype), 2 and 3 - G/C (heterozygous), and 4 - C/C(homozygous) (TIF 4408 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Punja, H.K., Nanjappa, D.P., Babu, N. et al. TP53 codon 72 polymorphism and type 2 diabetes: a case–control study in South Indian population. Mol Biol Rep 48, 5093–5097 (2021). https://doi.org/10.1007/s11033-021-06505-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-021-06505-8

Keywords

Search

Navigation